This content is in French.
Breast cancer: shorter radiotherapy becomes the new global standard
12 mars 2026
By Elodie Vaz | Published on March 12, 2026 | 4 min
read
Breast cancer remains the most common cancer in women. In France, around 60,000 new cases are diagnosed each year, about one third of them at the locoregional stage. In these situations, treatment classically relies on surgery followed by radiotherapy targeting the breast or chest wall as well as the lymph node areas.
Until recently, the reference regimen consisted of 25 radiotherapy sessions delivered over five weeks. The final results of a French phase III trial, published in March 2026 in The Lancet after five years of follow-up, could profoundly change this therapeutic strategy worldwide.
Breast cancer remains the most common cancer in women. In France, around 60,000 new cases are diagnosed each year, about one third of them at the locoregional stage. In these situations, treatment classically relies on surgery followed by radiotherapy targeting the breast or chest wall as well as the lymph node areas.
Until recently, the reference regimen consisted of 25 radiotherapy sessions delivered over five weeks. The final results of a French phase III trial, published in March 2026 in The Lancet after five years of follow-up, could profoundly change this therapeutic strategy worldwide.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Rivera S, et al. 5-year results of hypofractionated locoregional radiotherapy in early breast cancer (HypoG-01 – UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial. Lancet. 2026;407:976-987.
View the source
